Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft...

Area of Science:

• Pulmonary Medicine
• Transplant Surgery
• Immunomodulation

Background:

• Bronchiolitis obliterans (BO) is a significant cause of lung transplant failure.
• Refractory cases of BO present a therapeutic challenge.
• Extracorporeal photopheresis (ECP) is explored as a treatment option.

Purpose of the Study:

• To prospectively evaluate the efficacy of ECP in attenuating FEV1 decline in lung transplant recipients with refractory BO.
• To assess the impact of ECP on mortality rates.
• To analyze the relationship between FEV1 decline and survival.

Main Methods:

• Prospective evaluation of lung transplant recipients with refractory BO across 10 centers.
• Assignment to ECP treatment or observation based on spirometric criteria, with crossover allowed.
• Primary endpoint: >50% reduction in FEV1 decline rate at 6 months post-ECP initiation. Secondary endpoint: mortality at 6 and 12 months.

Main Results:

• 95% of ECP-treated patients showed a response, with a 93% reduction in FEV1 decline rate.
• Overall mortality at 6 and 12 months was 32% and 41%, respectively, primarily due to respiratory or graft failure.
• Non-survivors exhibited significantly higher FEV1 decline rates compared to survivors.

Conclusions:

• ECP demonstrates significant efficacy in reducing FEV1 decline in lung transplant recipients with refractory BO.
• Earlier detection and treatment of BO are crucial for improving patient outcomes with ECP.
• The findings support considering ECP for refractory BO to mitigate lung function deterioration.